WO2004035778A1 - フォンビルブランド因子切断酵素の特異的基質および活性測定法 - Google Patents
フォンビルブランド因子切断酵素の特異的基質および活性測定法 Download PDFInfo
- Publication number
- WO2004035778A1 WO2004035778A1 PCT/JP2002/010816 JP0210816W WO2004035778A1 WO 2004035778 A1 WO2004035778 A1 WO 2004035778A1 JP 0210816 W JP0210816 W JP 0210816W WO 2004035778 A1 WO2004035778 A1 WO 2004035778A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adamts
- substrate polypeptide
- amino acid
- substrate
- acid sequence
- Prior art date
Links
- 239000000758 substrate Substances 0.000 title claims abstract description 169
- 108091005670 ADAMTS13 Proteins 0.000 title claims abstract description 105
- 238000000034 method Methods 0.000 title claims abstract description 27
- 230000000694 effects Effects 0.000 title claims description 59
- 102100032290 A disintegrin and metalloproteinase with thrombospondin motifs 13 Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 189
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 181
- 229920001184 polypeptide Polymers 0.000 claims abstract description 180
- 150000001413 amino acids Chemical class 0.000 claims abstract description 69
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 102000043853 ADAMTS13 Human genes 0.000 claims description 101
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 57
- 101100156611 Homo sapiens VWF gene Proteins 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 239000007790 solid phase Substances 0.000 claims description 10
- 102000029750 ADAMTS Human genes 0.000 claims description 6
- 108091022879 ADAMTS Proteins 0.000 claims description 6
- 238000000691 measurement method Methods 0.000 claims description 6
- 238000007792 addition Methods 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 102100036664 Adenosine deaminase Human genes 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 238000011002 quantification Methods 0.000 abstract description 5
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 abstract description 2
- 238000005215 recombination Methods 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 52
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 28
- 108010047303 von Willebrand Factor Proteins 0.000 description 26
- 102100036537 von Willebrand factor Human genes 0.000 description 26
- 229960001134 von willebrand factor Drugs 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000003776 cleavage reaction Methods 0.000 description 13
- 230000007017 scission Effects 0.000 description 13
- 102000037865 fusion proteins Human genes 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 239000013615 primer Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 238000001042 affinity chromatography Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 238000010188 recombinant method Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 102000029791 ADAM Human genes 0.000 description 3
- 108091022885 ADAM Proteins 0.000 description 3
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 101001026137 Cavia porcellus Glutathione S-transferase A Proteins 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 101000870531 Pleuronectes platessa Glutathione S-transferase A Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 241000672609 Escherichia coli BL21 Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PMHUSCHKTSTQEP-UHFFFAOYSA-N (4-carbamimidoylphenyl)methanesulfonyl fluoride Chemical compound NC(=N)C1=CC=C(CS(F)(=O)=O)C=C1 PMHUSCHKTSTQEP-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 102000051388 ADAMTS1 Human genes 0.000 description 1
- 108091005660 ADAMTS1 Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- PSZNHSNIGMJYOZ-WDSKDSINSA-N Asp-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PSZNHSNIGMJYOZ-WDSKDSINSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 101000801195 Homo sapiens TLE family member 5 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000035888 Immune-mediated thrombotic thrombocytopenic purpura Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 229910003797 SPO1 Inorganic materials 0.000 description 1
- 101100150136 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SPO1 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000004886 acquired thrombotic thrombocytopenic purpura Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 102000056245 human TLE5 Human genes 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 101150019841 penP gene Proteins 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2002/010816 WO2004035778A1 (ja) | 2002-10-18 | 2002-10-18 | フォンビルブランド因子切断酵素の特異的基質および活性測定法 |
JP2004544704A JP3944586B2 (ja) | 2002-10-18 | 2002-10-18 | フォンビルブランド因子切断酵素の特異的基質および活性測定法 |
US10/531,427 US7718763B2 (en) | 2002-10-18 | 2002-10-18 | Substrate polyeptides for von Willebrand factor cleaving protease ADAMTS-13 |
AU2002344102A AU2002344102A1 (en) | 2002-10-18 | 2002-10-18 | Substrates specific to von willebrand factor cleaving protease and method of assaying the activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2002/010816 WO2004035778A1 (ja) | 2002-10-18 | 2002-10-18 | フォンビルブランド因子切断酵素の特異的基質および活性測定法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004035778A1 true WO2004035778A1 (ja) | 2004-04-29 |
Family
ID=32104830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/010816 WO2004035778A1 (ja) | 2002-10-18 | 2002-10-18 | フォンビルブランド因子切断酵素の特異的基質および活性測定法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7718763B2 (ja) |
JP (1) | JP3944586B2 (ja) |
AU (1) | AU2002344102A1 (ja) |
WO (1) | WO2004035778A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006019379A1 (en) * | 2004-07-19 | 2006-02-23 | American Diagnostica Inc. | Methods for measuring adamts13 activity and protein on platelets and in plasma |
WO2006085441A1 (ja) * | 2005-02-14 | 2006-08-17 | Japan Clinical Laboratories, Inc. | Adamts13活性検定用抗体及び活性検定方法 |
US7270976B2 (en) | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
JP2012510817A (ja) * | 2008-12-05 | 2012-05-17 | バクスター・インターナショナル・インコーポレイテッド | フォンビルブランド因子のadamts13媒介インビボ切断を測定する方法およびその使用 |
WO2021182171A1 (ja) | 2020-03-13 | 2021-09-16 | テルモ株式会社 | ポンプによる血液循環を行う医療機器における血栓の形成またはそのリスクを予測するための方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7468258B2 (en) * | 2006-03-07 | 2008-12-23 | Wake Forest University Health Sciences | Self-quenching homofluorophore compositions for detecting enzyme activity |
DE102007031708A1 (de) | 2007-07-06 | 2009-01-08 | Dade Behring Marburg Gmbh | Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin |
US8945895B2 (en) | 2009-07-31 | 2015-02-03 | Baxter International Inc. | Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof |
EP3526339A1 (en) | 2016-10-11 | 2019-08-21 | Laboratory Corporation of America Holdings | Methods and systems for determining adamts13 enzyme activity |
EP3548899B1 (en) * | 2016-11-30 | 2023-10-18 | BERBI Biomedizinische Forschung, Entwicklung und Beratung Gesellschaft m.b.H. | Rapid semiquantitative method for determining adamts-13 activity in a patient plasma sample |
EP4279607A1 (de) | 2022-05-20 | 2023-11-22 | Siemens Healthcare Diagnostics Products GmbH | Enzym-verstärkter adamts-13 aktivitätstest |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849536A (en) * | 1990-03-02 | 1998-12-15 | Bio-Technology General Corp. | Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same |
-
2002
- 2002-10-18 US US10/531,427 patent/US7718763B2/en not_active Expired - Lifetime
- 2002-10-18 AU AU2002344102A patent/AU2002344102A1/en not_active Abandoned
- 2002-10-18 JP JP2004544704A patent/JP3944586B2/ja not_active Expired - Lifetime
- 2002-10-18 WO PCT/JP2002/010816 patent/WO2004035778A1/ja active Application Filing
Non-Patent Citations (5)
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1779117A4 (en) * | 2004-07-19 | 2008-02-20 | American Diagnostica Inc | METHOD FOR MEASURING ADAMTS13 ACTIVITY AND PROTEIN ON BLOOD PLATES AND IN PLASMA |
WO2006019379A1 (en) * | 2004-07-19 | 2006-02-23 | American Diagnostica Inc. | Methods for measuring adamts13 activity and protein on platelets and in plasma |
EP1779117A1 (en) * | 2004-07-19 | 2007-05-02 | American Diagnostica Inc. | Methods for measuring adamts13 activity and protein on platelets and in plasma |
US7270976B2 (en) | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
JP4913034B2 (ja) * | 2005-02-14 | 2012-04-11 | アルフレッサファーマ株式会社 | Adamts13活性検定用抗体及び活性検定方法 |
US7833726B2 (en) | 2005-02-14 | 2010-11-16 | Alfresa Pharma Corporation | Antibody for assaying ADAMTS13 activity and method for assaying the activity |
WO2006085441A1 (ja) * | 2005-02-14 | 2006-08-17 | Japan Clinical Laboratories, Inc. | Adamts13活性検定用抗体及び活性検定方法 |
JP2012082210A (ja) * | 2005-02-14 | 2012-04-26 | Alfresa Pharma Corp | Adamts13活性検定用抗体及び活性検定方法 |
JP2012510817A (ja) * | 2008-12-05 | 2012-05-17 | バクスター・インターナショナル・インコーポレイテッド | フォンビルブランド因子のadamts13媒介インビボ切断を測定する方法およびその使用 |
JP2015213513A (ja) * | 2008-12-05 | 2015-12-03 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | フォンビルブランド因子のadamts13媒介インビボ切断を測定する方法およびその使用 |
JP2017153490A (ja) * | 2008-12-05 | 2017-09-07 | バクスアルタ インコーポレイテッド | フォンビルブランド因子のadamts13媒介インビボ切断を測定する方法およびその使用 |
JP2020022515A (ja) * | 2008-12-05 | 2020-02-13 | バクスアルタ インコーポレイテッド | フォンビルブランド因子のadamts13媒介インビボ切断を測定する方法およびその使用 |
WO2021182171A1 (ja) | 2020-03-13 | 2021-09-16 | テルモ株式会社 | ポンプによる血液循環を行う医療機器における血栓の形成またはそのリスクを予測するための方法 |
Also Published As
Publication number | Publication date |
---|---|
US20070065895A1 (en) | 2007-03-22 |
AU2002344102A1 (en) | 2004-05-04 |
JPWO2004035778A1 (ja) | 2006-02-16 |
JP3944586B2 (ja) | 2007-07-11 |
US7718763B2 (en) | 2010-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Oikawa et al. | Activation of mammalian IRE1α upon ER stress depends on dissociation of BiP rather than on direct interaction with unfolded proteins | |
US6399358B1 (en) | Human gene encoding human chondroitin 6-sulfotransferase | |
CA2457059A1 (en) | System for detecting protease | |
US10538802B2 (en) | Polypeptide substrate for the detection of von Williebrand factor cleaving protease ADAMTS13 | |
CA2464121C (en) | Pregnancy-associated plasma protein-a2 (papp-a2) | |
WO2004035778A1 (ja) | フォンビルブランド因子切断酵素の特異的基質および活性測定法 | |
Stubbs et al. | Encoding of human basic and glycosylated proline-rich proteins by the PRB gene complex and proteolytic processing of their precursor proteins | |
US20230043763A1 (en) | Nucleic Acids, Methods and Kits for the Diagnosis of DYT6 Primary Torsion Dystonia | |
KR20100059897A (ko) | 심혈관 및 혈전 위험도를 측정하기 위한 clec1b의 용도 | |
EP1567647B1 (en) | Soluble notch-based substrates for gamma secretase and methods and compositions for using same | |
JPH11508442A (ja) | ヒト腺性カリクレイン−1(hK2) | |
US7122186B2 (en) | Human serine protease | |
Patel et al. | In vitro assay for site-specific proteases using bead-attached GFP substrate | |
JP2002300880A (ja) | 新規ユビキチン特異プロテアーゼ | |
EP1378518A1 (en) | RGS2 as a biomarker for macrophage activation and for activated-macrophage-related disorder | |
CA2351312A1 (en) | Novel human wnt gene | |
WO2001038353A2 (en) | Human wnt gene | |
US20020123103A1 (en) | Human Wnt gene | |
JPH10243784A (ja) | Ii型膜蛋白質をコードする遺伝子の同定方法 | |
EP1514945A1 (en) | CD38 as a molecular marker on macrophages for COPD, and as a target molecule for treatment of COPD | |
US20020164764A1 (en) | Transmembrane polypeptide expressed by lymphocytes | |
JP2003517269A (ja) | インスリン様生長因子結合タンパク質を選択的に開裂し得る新規セリンプロテアーゼ | |
Ahmad et al. | MUTATION ON WD DIPEPTIDE MOTIFS OF THE p48 SUBUNIT OF CHROMATIN ASSEMBLY FACTOR-1 CAUSING VIABILITY AND GROWTH OF DT40 CHICKEN B CELL LINE | |
Böhm | Targeting the Final Step of Blood Coagulation: Structure-Activity-Relationship Studies on the Factor XIIIa Inhibitor Tridegin | |
Annereau | Inventor: John L. Teem, Tallahassee, FL (US) Assignee: Florida State University Research Foundation, Tallahassee, FL (US) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004544704 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007065895 Country of ref document: US Ref document number: 10531427 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10531427 Country of ref document: US |